The cytochrome P450 (CYP) family of enzymes performs the primary metabolism of many drugs in the human body. One of these CYP enzymes, CYP2C19, is responsible for the metabolism of a wide variety of drugs including the anti-blood clotting drug Plavix (Clopidogrel). CYP2C19 is required to convert Plavix, a prodrug, to its active form. Patients who have poor CYP2C19 activities will not effectively convert Plavix to its active form. Plavix will have low efficacy in those patients in preventing heart attack, stroke, and cardiovascular death. The Food and Drug Administration (FDA) added a boxed warning to the label of Plavix, alerting patients and doctors of the reduced effectiveness in patients who are poor metabolizers of Plavix (poor CYP2C19 activities)1. It is estimated that 2 to 14% of the population are poor metabolizers; the rate varies based on racial background.
The drug levels and antiplatelet effects of Plavix differ depending on the genotype of the CYP2C19 enzyme. The following represent the different alleles of CYP2C19 that make up a patient's genotype1:
References
Sibbing D et al. (2010). Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in Clopidogrel-treated patients with coronary stent placement. Circulation. 121:51